90 related articles for article (PubMed ID: 4960865)
1. Further investigations on the immunogenic activity of aqueous and aluminum oxide adsorbed inactivated poliovirus vaccines in Macaca mulatta.
Drescher J; Grützner L; Godglück G
Am J Epidemiol; 1967 May; 85(3):413-23. PubMed ID: 4960865
[No Abstract] [Full Text] [Related]
2. Immunogenic activity of aqueous and aluminum oxide adsorbed poliovirus vaccine in Macaca mulatta.
HENNEBERG G; DRESCHER J; GODGLUECK G; GRUETZNER L
Am J Hyg; 1962 Jan; 75():44-55. PubMed ID: 13906466
[No Abstract] [Full Text] [Related]
3. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing capacity of poliovirus type 3 antibodies tested against 5 different intratypic variants of poliovirus type 3. A comparative study in children immunized with live, inactivated, or both types of poliovirus vaccines.
Böttiger M
Arch Gesamte Virusforsch; 1971; 35(2):251-5. PubMed ID: 4332939
[No Abstract] [Full Text] [Related]
5. [Effects of aluminum hydroxide on the immunizing properties of inactivated poliomyelitis vaccine].
HAAS R; DOSTAL V; SAUTHOFF R
Klin Wochenschr; 1955 Dec; 33(45-46):1082-4. PubMed ID: 13287015
[No Abstract] [Full Text] [Related]
6. First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age.
Lindgren LM; Tingskov PN; Justesen AH; Nedergaard BS; Olsen KJ; Andreasen LV; Kromann I; Sørensen C; Dietrich J; Thierry-Carstensen B
Vaccine; 2017 Jan; 35(4):596-604. PubMed ID: 28027810
[TBL] [Abstract][Full Text] [Related]
7. [Enhancing the immunogenicity of inactivated polio vaccines with chitosan used as an adjuvant].
Gendon IuZ; Markushin SG; Akopova II; Krivtsov GG; Akhmatova NK; Koptiaeva IB; Vasil'ev IuM
Vopr Virusol; 2011; 56(6):28-32. PubMed ID: 22359946
[TBL] [Abstract][Full Text] [Related]
8. [Experiments with depot vaccines].
Henneberg G
Arzneimittelforschung; 1965 Sep; 15(9):1003-8. PubMed ID: 4955784
[No Abstract] [Full Text] [Related]
9. Inactivated vaccines based on alternatives to wild-type seed virus.
Chumakov K; Dragunsky E; Ivshina A; Enterline J; Wells V; Nomura T; Gromeier M; Wimmer E
Dev Biol (Basel); 2001; 105():171-7. PubMed ID: 11763325
[No Abstract] [Full Text] [Related]
10. Immunization against poliomyelitis.
Beale AJ
Br Med Bull; 1969 May; 25(2):148-52. PubMed ID: 4319086
[No Abstract] [Full Text] [Related]
11. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults.
Soonawala D; Verdijk P; Wijmenga-Monsuur AJ; Boog CJ; Koedam P; Visser LG; Rots NY
Vaccine; 2013 Aug; 31(36):3688-94. PubMed ID: 23770332
[TBL] [Abstract][Full Text] [Related]
12. [Poliomyelitis: immunologic bases and prophylactic deductions].
Lemoine E; Antoine M; Larribaud J
Rev Corps Sante Armees Terre Mer Air; 1969 Aug; 10(4):383-98. PubMed ID: 4315758
[No Abstract] [Full Text] [Related]
13. [Calcium phosphate as adjuvant in vaccinations in man].
Relyveld EH; Martin R; Raynaud M; Damas JP; Thérond C; Hénocq E; Romain F; Turpin A; Céolin G; Chevé J; Digeon M; Cheyroux M
Ann Inst Pasteur (Paris); 1969 Mar; 116(3):300-26. PubMed ID: 5771871
[No Abstract] [Full Text] [Related]
14. [Findings on the success of vaccination and revaccination with live and inactivated vaccines against poliomyelitis].
Dostal V; Haenzel I; Sturm W
Schweiz Med Wochenschr; 1969 Sep; 99(37):1322-4. PubMed ID: 4309326
[No Abstract] [Full Text] [Related]
15. [Antipoliomyelitis vaccination of young children with a new inactivated vaccine. Serological results].
Grenier B; Viarme F; Roumiantzeff M; Xueref C; Demont F
Arch Fr Pediatr; 1985 Apr; 42(4):321-3. PubMed ID: 4004496
[TBL] [Abstract][Full Text] [Related]
16. [Control of poliomyelitis. I. Retrospective view and current situation in the world with special reference to our country].
Vecchi C
Ann Sclavo; 1972; 14(6):665-93. PubMed ID: 4360237
[No Abstract] [Full Text] [Related]
17. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
Yang C; Shi H; Zhou J; Liang Y; Xu H
Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
[TBL] [Abstract][Full Text] [Related]
18. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
[TBL] [Abstract][Full Text] [Related]
19. An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication.
Minor PD
Methods Mol Biol; 2016; 1387():1-10. PubMed ID: 26983727
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart.
Embree J; Law B; Voloshen T; Tomovici A
Clin Vaccine Immunol; 2015 Mar; 22(3):282-90. PubMed ID: 25540274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
